Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board
- PMID: 18490257
- DOI: 10.1188/08.CJON.S1.53-62
Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board
Abstract
Steroids have been the foundation of multiple myeloma therapy for more than 30 years and continue to be prescribed as single agents and in combination with other antimyeloma drugs, including novel therapies. Steroids cause a wide range of side effects that affect almost every system of the body. Identification and prompt management of the toxicities contribute to the success of steroid-containing antimyeloma regimens. By following patients carefully and educating them and their caregivers, nurses can promote adherence to therapy and improve quality of life. The International Myeloma Foundation's Nurse Leadership Board developed this consensus statement for the management of steroid-associated side effects to be used by healthcare providers in any medical setting.
Similar articles
-
Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):37-52. doi: 10.1188/08.CJON.S1.37-51. Clin J Oncol Nurs. 2008. PMID: 18490256
-
Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):13-20. doi: 10.1188/08.CJON.S1.13-19. Clin J Oncol Nurs. 2008. PMID: 18490253
-
Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):21-8. doi: 10.1188/08.CJON.S1.21-27. Clin J Oncol Nurs. 2008. PMID: 18490254
-
Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board.Clin J Oncol Nurs. 2011 Aug;15 Suppl(Suppl):5-8. doi: 10.1188/11.S1.CJON.5-8. Clin J Oncol Nurs. 2011. PMID: 21816706 Free PMC article.
-
Lenalidomide and its role in the management of multiple myeloma.Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865. Expert Rev Anticancer Ther. 2008. PMID: 18533796 Review.
Cited by
-
Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma.Cancer Nurs. 2011 May-Jun;34(3):219-27. doi: 10.1097/NCC.0b013e3181f9904d. Cancer Nurs. 2011. PMID: 21522061 Free PMC article.
-
Risk factors for falls in hospitalized patients with cancer: A systematic review and meta-analysis.Asia Pac J Oncol Nurs. 2022 Jun 29;9(8):100107. doi: 10.1016/j.apjon.2022.100107. eCollection 2022 Aug. Asia Pac J Oncol Nurs. 2022. PMID: 36033969 Free PMC article. Review.
-
Treatment of older adult or frail patients with multiple myeloma.Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):46-54. doi: 10.1182/hematology.2021000231. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889397 Free PMC article.
-
Overview and experience of a nursing e-mentorship program.Clin J Oncol Nurs. 2011 Aug;15(4):418-23. doi: 10.1188/11.CJON.418-423. Clin J Oncol Nurs. 2011. PMID: 21810575 Free PMC article.
-
New agents in the Treatment of Myeloma Bone Disease.Calcif Tissue Int. 2018 Feb;102(2):196-209. doi: 10.1007/s00223-017-0351-7. Epub 2017 Nov 2. Calcif Tissue Int. 2018. PMID: 29098361 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical